Drug Profile
Research programme: cancer therapeutics - Beactica/Boehringer Ingelheim
Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Beactica; Boehringer Ingelheim
- Class Small molecules
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for research development in Cancer in Sweden
- 31 Jan 2019 Research programme: cancer therapeutics is available for licensing as of 31 Jan 2019. http://www.beactica.com/pipeline
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Sweden